<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Manag Res</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Manag Res</journal-id><journal-id journal-id-type="publisher-id">Cancer Management and Research</journal-id><journal-title-group><journal-title>Cancer Management and Research</journal-title></journal-title-group><issn pub-type="epub">1179-1322</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29760565</article-id><article-id pub-id-type="pmc">5937480</article-id><article-id pub-id-type="doi">10.2147/CMAR.S163209</article-id><article-id pub-id-type="publisher-id">cmar-10-953</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liao</surname><given-names>Xiwen</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref><xref ref-type="author-notes" rid="fn1-cmar-10-953">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yu</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref><xref ref-type="author-notes" rid="fn1-cmar-10-953">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoguang</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref><xref ref-type="aff" rid="af2-cmar-10-953">2</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Chuangye</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Tingdong</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Chengkun</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Guangzhi</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="af1-cmar-10-953">1</xref><xref ref-type="corresp" rid="c1-cmar-10-953"/></contrib></contrib-group><aff id="af1-cmar-10-953">
<label>1</label>Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, People&#x02019;s Republic of China</aff><aff id="af2-cmar-10-953">
<label>2</label>Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-cmar-10-953">Correspondence: Tao Peng, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Shuang Yong Road 6, Nanning 530021, Guangxi Zhuang Autonomous Region, China, Tel +86 771 535 6528, Fax +86 771 535 0031, Email <email>pengtaogmu@163.com</email></corresp><fn id="fn1-cmar-10-953"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>01</day><month>5</month><year>2018</year></pub-date><volume>10</volume><fpage>953</fpage><lpage>967</lpage><permissions><copyright-statement>&#x000a9; 2018 Liao et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>The aim of this investigation was to identify candidate single nucleotide polymorphisms (SNPs) and molecular pathways associated with tumor protein p53 (TP53) expression status in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), clarify their potential mechanisms, and generate SNP-to-gene to pathway hypothesis.</p></sec><sec><title>Materials and methods</title><p>Identify candidate Causal SNPs and Pathways (ICSNPathway) was used to perform pathway analysis based on the results of our previous genome-wide association study of TP53 expression status in 387 HBV-related HCC patients.</p></sec><sec><title>Results</title><p>Through the ICSNPathway analysis, we identified 18 candidate SNPs and 10 candidate pathways that are associated with TP53 expression status in HBV-related HCC. The strongest mechanism involved the modulation of major histocompatibility complex, class II, DP beta 1 (human leukocyte antigen [<italic>HLA</italic>]-<italic>DPB1</italic>-rs1042153), major histocompatibility complex, class II, DQ beta 1 (<italic>HLA-DQB1</italic>-rs1130399, <italic>HLA-DQB1</italic>-rs1049056, <italic>HLA-DQB1</italic>-rs1049059, and <italic>HLA-DQB1</italic>-rs1049060), and major histocompatibility complex, class II, DR beta 1 (<italic>HLA-DRB1</italic>-rs35445101). SNPs consequently affected regulatory roles in all the candidate pathways except hematopoietic cell lineage pathways. Association analysis using the GSE14520 data set, Gene Multiple Association Network Integration Algorithm, and Search Tool for the Retrieval of Interacting Genes/Proteins suggests that all genes of the candidate SNPs were associated with <italic>TP53</italic>. Survival analysis showed that the collagen type VI alpha 3 chain (<italic>COL6A3</italic>) rs111231885 and <italic>COL6A3</italic>-rs113155945 and <italic>COL6A3</italic> block 4 CC haplotypes with TP53 negative status may have protective effects in HBV-related HCC patients after hepatectomy.</p></sec><sec><title>Conclusion</title><p>Our pathway analysis identified 18 candidate SNPs and 10 candidate pathways that were associated with TP53 expression status in HBV-related HCC. Among these candidate SNPs, the genetic variation of <italic>COL6A3</italic> may be a potential prognostic biomarker of HBV-related HCC.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>TP53</kwd><kwd>hepatocellular carcinoma</kwd><kwd>hepatitis B virus</kwd><kwd>genome-wide association study</kwd><kwd>pathway analysis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Liver cancer is the third leading cause of cancer death in China, with an age-standardized 5-year relative survival rate of 10.1%.<xref rid="b1-cmar-10-953" ref-type="bibr">1</xref>,<xref rid="b2-cmar-10-953" ref-type="bibr">2</xref> The majority of liver cancer cases are hepatocellular carcinoma (HCC).<xref rid="b3-cmar-10-953" ref-type="bibr">3</xref> A high prevalence of hepatitis B virus (HBV) infection and aflatoxin B1 exposure are the main factors of HCC in the Guangxi province of China.<xref rid="b4-cmar-10-953" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-cmar-10-953" ref-type="bibr">6</xref> Previous studies have demonstrated that the tumor protein p53 (<italic>TP53</italic>) mutation is frequently found in HBV-related HCC in patients of Guangxi province.<xref rid="b7-cmar-10-953" ref-type="bibr">7</xref>&#x02013;<xref rid="b10-cmar-10-953" ref-type="bibr">10</xref> Therefore, in the Guangxi region, there is a representative population in which the associations between HBV infection and the <italic>TP53</italic> gene in HCC can be investigated.</p><p>Hepatocarcinogenesis is driven by the interaction of genetic and environmental factors.<xref rid="b11-cmar-10-953" ref-type="bibr">11</xref>,<xref rid="b12-cmar-10-953" ref-type="bibr">12</xref> Genome-wide association studies (GWAS) can be used to identify associations between specific single nucleotide polymorphisms (SNPs) and complex diseases or other traits.<xref rid="b13-cmar-10-953" ref-type="bibr">13</xref> The roles of the corresponding genes or proteins in the context of the pathway might be altered by trait-related SNPs. Identify candidate Causal SNPs and Pathways (ICSNPathway) is an analytical framework for the comprehensive interpretation of GWAS data by integrating linkage disequilibrium (LD) analysis, functional SNP annotation, and pathway-based analysis (PBA) and can be used to derive the mechanism hypothesis of SNP&#x02192;gene&#x02192;pathway(s) for complex disease studies, including cancer.<xref rid="b14-cmar-10-953" ref-type="bibr">14</xref> In addition, ICSNPathway also is a tool based on PBA algorithm, which is a method for secondary excavation of GWAS results based on prior biological knowledge on gene function and biological metabolic pathways.<xref rid="b14-cmar-10-953" ref-type="bibr">14</xref> By using the PBA algorithm, more information about the pathway and gene sets with same functions which are associated with the diseases or traits from GWAS results could be obtained.</p><p>Our previous study has identified several SNPs associated with TP53 expression status in HBV-related HCC in patients of Guangxi by using the GWAS approach.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> In the present study, we further investigated candidate SNPs and molecular pathways associated with TP53 expression status in HBV-related HCC by using the ICSNPathway web server based on the result of our previous GWAS.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="methods"><title>Study population and GWAS data</title><p>Our study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University with an ethics approval number of 2015 (KY-E-032).<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> Written informed consent was obtained from all the participants enrolled in the study. The primary GWAS data set was extracted from our previous study.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> Clinicopathological characteristics and prognosis of the HBV-related HCC patients, genotyping, quality control, and GWAS analysis methods have been described and published in our earlier article.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> A total of 403 patients with serum tests that were HBV surface antigen positive and newly diagnosed with HCC by pathological examination in the First Affiliated Hospital of Guangxi Medical University between 2001 and 2013 were included.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> TP53 staining in HCC tumor tissues was detected by immunohistochemistry.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> The SNPs were genotyped by an Illumina Human Exome BeadChip 12 v1-1 system (Illumina Inc, San Diego, CA, USA). Quality control standards were set as follows: samples were excluded if they had 1) an overall genotyping rate of &#x0003c;95%; 2) ambiguous gender; 3) genome-wide identity by-descent &#x0003e;0.1875; 4) outliers in principal component analysis (PCA) for ancestry and population stratification. SNPs had to meet the following criteria: 1) a call rate of &#x0003e;95%; 2) a Hardy&#x02013;Weinberg equilibrium <italic>P</italic>&#x0003e;1&#x000d7;10<sup>&#x02212;6</sup>; 3) a minor allele frequency &#x0003e;0.01.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> PCA for ancestry and population stratification suggest that no or mild population stratification was found in the current study population, and similar results were observed in our previous study.<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> A total of 387 patients with 28,952 SNPs passed the quality control filters and were included in further investigations.</p></sec><sec><title>Identification of candidate SNPs and pathways</title><p>The ICSNPathway (<ext-link ext-link-type="uri" xlink:href="http://icsnpathway.psych.ac.cn">http://icsnpathway.psych.ac.cn</ext-link>, accessed February 20, 2017) web server contains a two-stage analysis: 1) preselect candidate SNPs by LD analysis and functional SNP annotation based on the most significant SNPs and 2) annotate the biological mechanisms for the preselected candidate SNPs by using PBA.<xref rid="b14-cmar-10-953" ref-type="bibr">14</xref> A complete list of GWAS SNP <italic>P</italic>-values was input for ICSNPathway analysis. The parameters used in the ICSNPathway were 1) threshold to specify the most significant SNPs: <italic>P</italic>-value &#x0003c;1&#x000d7;10<sup>&#x02212;2</sup>; 2) Hap-Map population: Han Chinese in Beijing, China; 3) LD cut-off: <italic>r</italic><sup>2</sup>&#x0003e;0.8; 4) distance for searching LD neighborhoods: 200 kb; 5) rule of mapping SNPs to genes: 500 kb upstream and downstream of gene; 6) pathway/gene set database: Kyoto Encyclopedia of Genes and Genomes; 7) number of genes in each pathway/gene set: minimum 5 and maximum 100; and 8) false discovery rate cutoff for PBA: 0.1.</p></sec><sec sec-type="methods"><title>Association analysis</title><p>Based on the results of the ICSNPathway analysis, haplotype analysis among the candidate SNPs was calculated using Haploview version 4.2 (Broad Institute of MIT and Harvard, Cambridge, MA, USA).<xref rid="b16-cmar-10-953" ref-type="bibr">16</xref> Regional LD plots of the candidate SNPs were generated by SNP Annotation and Proxy Search (SNAP) (<ext-link ext-link-type="uri" xlink:href="http://archive.broadinstitute.org/mpg/snap">http://archive.broadinstitute.org/mpg/snap</ext-link>, accessed February 20, 2017), a tool used for the identification and annotation of proxy SNPs using HapMap.<xref rid="b17-cmar-10-953" ref-type="bibr">17</xref> Genotype and haplotype distribution of the candidate SNPs in different TP53 expression status groups were determined using a binary logistic regression model. Co-expression analysis of the <italic>TP53</italic> gene and the genes of candidate SNPs was performed using GSE14520, a Chinese HBV-related HCC mRNA expression chip data set obtained from Gene Expression Omnibus (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo">https://www.ncbi.nlm.nih.gov/geo</ext-link>, accessed February 20, 2017).<xref rid="b18-cmar-10-953" ref-type="bibr">18</xref>,<xref rid="b19-cmar-10-953" ref-type="bibr">19</xref> In order to eliminate the batch effect of the expression chip, we only included the Affymetrix HT Human Genome U133A Array data set (Thermo Fisher Scientific, Waltham, MA, USA) of GSE14520 in the co-expression analysis. Gene Multiple Association Network Integration Algorithm<xref rid="b20-cmar-10-953" ref-type="bibr">20</xref>,<xref rid="b21-cmar-10-953" ref-type="bibr">21</xref> (GeneMANIA; <ext-link ext-link-type="uri" xlink:href="http://genemania.org">http://genemania.org</ext-link>, accessed February 20, 2017) and Search Tool for the Retrieval of Interacting Genes/Proteins<xref rid="b22-cmar-10-953" ref-type="bibr">22</xref>,<xref rid="b23-cmar-10-953" ref-type="bibr">23</xref> (STRING; <ext-link ext-link-type="uri" xlink:href="http://string.embl.de/">http://string.embl.de/</ext-link>, accessed February 20, 2017) web servers were used for investigating the gene&#x02013;gene and protein&#x02013;protein interactions (PPIs) among genes of the candidate SNPs, respectively.</p></sec><sec sec-type="methods"><title>Survival analysis</title><p>We further analyzed the association of the candidate SNPs and clinical outcomes. The TP53 expression status and the candidate SNP interactions were analyzed using a joint effects survival analysis. In addition, we also analyzed haplotypes of the candidate SNPs.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Pearson correlation coefficient was used to assess co-expression correlation. The odds ratio (OR) and the corresponding 95% confidence interval (CI) of the binary logistic regression model were used to estimate the relative risk of TP53 expression status in HBV-related HCC. Univariate analysis between clinical features and overall survival (OS) were studied using the Kaplan&#x02013;Meier method with the log-rank test. Cox proportional hazards regression analysis was used to calculate the crude and adjusted hazard ratio (HR) and 95% CI in univariate and multivariate analyses, with adjustment for age, gender, race, body mass index (BMI), smoking status, drinking status, Barcelona Clinic Liver Cancer (BCLC) stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and portal vein tumor thrombus (PVTT). A value of <italic>P</italic>&#x0003c;0.05 was considered statistically significant. All the statistical analyses were conducted with SPSS version 20.0 software (IBM Corporation, Armonk, NY, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Candidate SNPs and pathways</title><p>Using the <italic>P</italic>-values of the 28,952 GWAS SNPs as input data, the ICSNPathway identified 18 SNPs as candidate SNPs (<xref ref-type="table" rid="t1-cmar-10-953">Table 1</xref>) and 10 pathways as candidate pathways (<xref ref-type="table" rid="t2-cmar-10-953">Table 2</xref>) that were associated with TP53 expression status in HBV-related HCC. All of the candidate SNPs were non-synonymous coding SNPs, and the alteration of four SNPs (desmoglein 3 [<italic>DSG3</italic>]-rs16961975, keratin 35 (<italic>KRT35)</italic>-rs2071601, <italic>KRT35</italic>-rs743686, and keratin 36 (<italic>KRT36</italic>)-rs2301354) was deleterious. The strongest mechanism involved the modulation of major histocompatibility complex, class II, DP beta 1 (human leukocyte antigen [<italic>HLA</italic>]-<italic>DPB1</italic>-rs1042153), major histocompatibility complex, class II, DQ beta 1 (<italic>HLA-DQB1</italic>-rs1130399, <italic>HLA-DQB1</italic>-rs1049056, <italic>HLA-DQB1</italic>-rs1049059, and <italic>HLA-DQB1</italic>-rs1049060) and major histocompatibility complex, class II, DR beta 1 (<italic>HLA-DRB1</italic>-rs35445101), consequently affecting their regulatory roles in all the candidate pathways except the hematopoietic cell lineage pathway. The second strongest hypothetical biological mechanism was that SNPs of major histocompatibility complex, class I, C (<italic>HLA-C</italic>-rs1131096 and <italic>HLA-C</italic>-rs1130838) influence the regulatory role of cell adhesion molecules (CAMs), autoimmune thyroid disease, allograft rejection, antigen processing and presentation, type I diabetes mellitus, and graft-versus-host disease pathways. Other multiple mechanisms presented in <xref ref-type="table" rid="t1-cmar-10-953">Tables 1</xref> and <xref ref-type="table" rid="t2-cmar-10-953">2</xref> indicated that alterations in candidate SNPs of collagen type VI alpha 3 chain (<italic>COL6A3</italic>)-rs111231885 and <italic>COL6A3</italic>-rs113155945, desmoglein 3 (<italic>DSG3</italic>)-rs16961975, keratin 32 (<italic>KRT32</italic>)-rs3744786), keratin 35 (<italic>KRT35</italic>)-rs2071601 and <italic>KRT35</italic>-rs743686, and keratin 36 (<italic>KRT36</italic>)-rs2301354 affect their regulatory roles in cell communication, whereas legumain (<italic>LGMN</italic>)-rs118128989 alterations affected the antigen processing and presentation pathway and interleukin 6 receptor (<italic>IL6R</italic>)-rs2228145, interleukin 7 receptor (<italic>IL7R</italic>)-rs6897932 alterations affected the hematopoietic cell lineage pathway.</p></sec><sec sec-type="methods"><title>Association analysis</title><p>In the output of candidate SNPs, <italic>KRT32</italic>-rs3744786 and <italic>KRT35</italic>-rs2071601 were not present in the original GWAS result. So, only 16 candidate SNPs and their corresponding genes were included in further association and survival analysis. Four haplotype blocks were detected in the haplotypes analysis (block 1 pairwise <italic>r</italic><sup>2</sup>=0.992, constituted by <italic>HLA-C</italic>-rs1130838 and <italic>HLA-C</italic>-rs1131096; block 2 pairwise <italic>r</italic><sup>2</sup>=0.121&#x02013;1.0, constituted by <italic>HLA-DRB1</italic>-rs35445101, <italic>HLA-DQB1</italic>-rs1130399, <italic>HLA-DQB1</italic>-rs1049060, <italic>HLA-DQB1</italic>-rs1049059, and <italic>HLA-DQB1</italic>-rs1049056; block 3 pairwise <italic>r</italic><sup>2</sup>=0.973, constituted by <italic>KRT35</italic>-rs743686 and <italic>KRT36</italic>-rs2301354; block 4 pairwise <italic>r</italic><sup>2</sup>=0.755, constituted by <italic>COL6A3</italic>-rs111231885 and <italic>COL6A3</italic>-rs113155945; <xref ref-type="fig" rid="f1-cmar-10-953">Figure 1A</xref>). Distribution of candidate SNPs in different TP53 expression status patients is shown in <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S1</ext-link>. After adjusting for age, gender, race, BMI, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT, all the SNPs were significantly associated with TP53 expression status in HBV-related HCC. Association analysis in four haplotypes demonstrated that GT in block 1, AGTCC and GATCC/other haplotypes in block 2, GA/other haplotypes in block 3, and TT/other haplotypes in block 4 had significantly decreased risk of TP53 expression status in HBV-related HCC, compared to patients with TC, AGAGA, AG, and CC (<xref ref-type="table" rid="t3-cmar-10-953">Table 3</xref>), respectively.</p><p>Co-expression analysis in HBV-related HCC expression profile data set from the GSE14520 cohort revealed that the <italic>TP53</italic> gene has a significantly weak negative correlation with <italic>HLA-C</italic> (<italic>r</italic>=&#x02212;0.322, <italic>P</italic>&#x0003c;0.001), <italic>IL6R</italic> (<italic>r</italic>=&#x02212;0.132, <italic>P</italic>=0.007), and <italic>KRT36</italic> (<italic>r</italic>=&#x02212;0.186, <italic>P</italic>&#x0003c;0.001), whereas it had a positive correlation with <italic>COL6A3</italic> (<italic>r</italic>=0.238, <italic>P</italic>&#x0003c;0.001), <italic>HLA-DPB1</italic> (<italic>r</italic>=0.115, <italic>P</italic>=0.018), <italic>HLA-DQB1</italic> (<italic>r</italic>=0.176, <italic>P</italic>=0.0003), and <italic>LGMN</italic> (<italic>r</italic>=0.157, <italic>P</italic>=0.001) at the mRNA level in HBV-related HCC of GSE14520; the co-expression heat map is shown in <xref ref-type="fig" rid="f1-cmar-10-953">Figure 1B</xref>. The remaining genes were not significantly correlated with <italic>TP53</italic> at the mRNA level. Gene and gene co-expression interaction networks constructed by GeneMANIA demonstrated that all the genes of the candidate SNPs exist in a complex gene&#x02013;gene co-expression interaction network and are directly or indirectly associated with <italic>TP53</italic> (<xref ref-type="fig" rid="f2-cmar-10-953">Figure 2A</xref>). In addition, PPIs determined experimentally and constructed by STRING showed that HLA-DQB1, HLA-C, KRT35, IL7R, and LGMN were associated with TP53 through ubiquitin C (UBC) (<xref ref-type="fig" rid="f2-cmar-10-953">Figure 2B</xref>).</p><p>Detailed regional LD plots of the four haplotype blocks of the candidate SNPs were generated by SNAP. Regional LD plots for four SNPs of HLA-DQB1 in block 2 are shown in <xref ref-type="fig" rid="f3-cmar-10-953">Figure 3A&#x02013;D</xref>, whereas the regional LD plot of <italic>HLA-DRB1</italic>-rs35445101 in block 2 was not available on the SNAP website. Regional LD plots of block 3 (<xref ref-type="fig" rid="f4-cmar-10-953">Figure 4A, B</xref>) and block 4 (<xref ref-type="fig" rid="f4-cmar-10-953">Figure 4C, D</xref>) are shown in <xref ref-type="fig" rid="f4-cmar-10-953">Figure 4</xref>, whereas the regional LD plot for block 1 of <italic>HLA-C</italic>-rs1131096 and <italic>HLA-C</italic>-rs1130838 was not available on the SNAP website. Regional LD plot for these SNPs indicated that there were strong LD loci of these blocks detectable in the region nearby them.</p></sec><sec sec-type="methods"><title>Survival analysis</title><p>Survival analysis was used to further investigate the associations between the candidate SNPs and haplotypes with HBV-related HCC prognosis. Clinicopathological characteristics and prognosis information of patients with HBV-related HCC have been described and published in an earlier article<xref rid="b15-cmar-10-953" ref-type="bibr">15</xref> and shown in <xref ref-type="table" rid="t4-cmar-10-953">Table 4</xref>. Survival analysis of <italic>COL6A3</italic>-rs111231885 showed that patients with the T allele had a shorter median survival time (MST) than those with the C allele (51 vs 33 months for CC vs TT/TC, log-rank <italic>P</italic>=0.012; <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S2</ext-link>). After adjusting for age, gender, race, BMI, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT in the Cox proportional hazards regression model, patients with the T allele had a significantly increased risk of death compared to those with the C allele (adjusted <italic>P</italic>=0.043, HR=1.64, 95% CI=1.015&#x02013;2.647; <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S2</ext-link>). Similar results were also observed with <italic>COL6A3</italic>-rs113155945; patients with the TT genotype had a significantly increased risk of death compared to the CC genotype (adjusted <italic>P</italic>=0.047, HR=4.281, 95% CI=1.017&#x02013;18.022; <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S2</ext-link>). In addition, joint effects analysis was also used to explore the SNPs and TP53 interaction in HBV-related HCC prognosis. TP53-negative patients with the <italic>COL6A3</italic>-rs111231885 T allele carriers had a significantly increased risk of death (adjusted <italic>P</italic>=0.034, HR=1.994, 95% CI=1.052&#x02013;3.778; <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S3</ext-link>) and a poor clinical outcome (MST: 33 vs 68 months for TT/TC vs CC, log-rank <italic>P</italic>=0.031; <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx">Table S3</ext-link>) in HBV-related HCC, compared to TP53-negative patients with C allele carriers. No other genotypes were significantly associated with OS in single and joint effects analysis.</p><p>Survival analysis for haplotypes of candidate SNPs is shown in <xref ref-type="fig" rid="f5-cmar-10-953">Figure 5A&#x02013;D</xref>, and indicated that patients with TT/other haplotypes in block 4 had a significantly shorter OS (MST: 33 vs 51 months for TT/other haplotypes vs CC, log-rank <italic>P</italic>=0.019; <xref ref-type="table" rid="t5-cmar-10-953">Table 5</xref>, <xref ref-type="fig" rid="f5-cmar-10-953">Figure 5D</xref>). Multivariate analyses of the Cox proportional hazards regression model suggest that patients with TT/other haplotypes in block 4 had increased risk of death in HBV-related HCC (adjusted <italic>P</italic>=0.07, HR=1.450, 95% CI=0.970&#x02013;2.167; <xref ref-type="table" rid="t5-cmar-10-953">Table 5</xref>), with a critically significant <italic>P</italic>-value, compared to patients with CC haplotypes. Joint effects analysis (<xref ref-type="fig" rid="f6-cmar-10-953">Figure 6A&#x02013;D</xref>) indicated that TP53-negative patients with TT/other haplotypes in block 4 had a significantly poor prognosis (MST: 33 vs 68 months for TT/other haplotypes vs CC haplotypes, log-rank <italic>P</italic>=0.047; <xref ref-type="table" rid="t6-cmar-10-953">Table 6</xref>, <xref ref-type="fig" rid="f6-cmar-10-953">Figure 6D</xref>) and increased risk of death in HBV-related HCC (adjusted <italic>P</italic>=0.047, HR=1.713, 95% CI =1.006&#x02013;2.918; <xref ref-type="table" rid="t6-cmar-10-953">Table 6</xref>), compared to TP53-negative patients with CC haplotypes. No other haplotypes were significantly associated with OS in single or joint effects analysis.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The GWAS approach is increasingly being used to discover the association between genes and disease. However, most GWAS have focused on SNPs with high statistical significance, whereas many other SNPs have received little attention and the full potential of these data have not been fully exploited.<xref rid="b24-cmar-10-953" ref-type="bibr">24</xref>,<xref rid="b25-cmar-10-953" ref-type="bibr">25</xref> Therefore, it is necessary to perform in-depth data mining with GWAS results. Genome-wide pathway analysis can investigate the GWAS SNPs through a SNP&#x02192;gene&#x02192;pathway approach to discover the overrepresented pathways in the GWAS data, which would consider rare variants, multi-omics, and interactions. In the current study, ICSNPathway analysis identified 18 candidate SNPs and 10 candidate pathways that are associated with TP53 expression status in HBV-related HCC. Five hypothetical biological mechanisms can be obtained from ICSNPathway analysis.</p><p>The strongest hypothetical biological mechanism found that the candidate SNPs of <italic>HLA-DPB1</italic>, <italic>HLA-DQB1</italic>, and <italic>HLA-DRB1</italic> affected their regulatory roles in all the candidate pathways except hematopoietic cell lineage pathway. The major histocompatibility complex class II molecule is a heterodimer consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. Previous studies have demonstrated that <italic>HLA-DPB1</italic> polymorphisms were significantly associated with the risk of HBV infection susceptibility,<xref rid="b26-cmar-10-953" ref-type="bibr">26</xref>,<xref rid="b27-cmar-10-953" ref-type="bibr">27</xref> whereas the distribution of the SNPs genotype frequencies was similar in HCC and chronic hepatitis B patients.<xref rid="b26-cmar-10-953" ref-type="bibr">26</xref>,<xref rid="b28-cmar-10-953" ref-type="bibr">28</xref> A case&#x02013;control study that compared persistence and natural clearance of HBV infection in a population indicated that the <italic>HLA-DPB1</italic>-rs9277535 A allele has a major effect on the risk of persistent HBV infection.<xref rid="b29-cmar-10-953" ref-type="bibr">29</xref> Subsequently, another study also reported that <italic>HLA-DPB1</italic>-rs9277535 was significantly related to HBV infection risks and increased HBV clearance possibility in a dose-dependent manner.<xref rid="b30-cmar-10-953" ref-type="bibr">30</xref> Furthermore, the polymorphisms of another HLA class II molecule, <italic>HLA-DQB1</italic>, were also associated with the development of chronic HBV infection and liver cirrhosis,<xref rid="b31-cmar-10-953" ref-type="bibr">31</xref> as well as the risk factor of HCC.<xref rid="b32-cmar-10-953" ref-type="bibr">32</xref>,<xref rid="b33-cmar-10-953" ref-type="bibr">33</xref> In addition, our previous study also showed that <italic>HLA-DQB1</italic> polymorphisms have a prognosis predictive value in HBV-related HCC patients undergoing hepatic resection.<xref rid="b34-cmar-10-953" ref-type="bibr">34</xref> Similar genetic susceptibility research on <italic>HLA-DRB1</italic> also demonstrated that polymorphisms in the <italic>HLA-DRB1</italic> gene were significantly associated with HCC risk, HBV infection, and progression from CHB to HCC.<xref rid="b35-cmar-10-953" ref-type="bibr">35</xref>&#x02013;<xref rid="b38-cmar-10-953" ref-type="bibr">38</xref></p><p>The second strongest mechanism was that a candidate SNP of <italic>HLA-C</italic>-rs1131096 and <italic>HLA-C</italic>-rs1130838 influenced the regulatory role of CAMs, autoimmune thyroid disease, allograft rejection, antigen processing and presentation, type I diabetes mellitus, and graft-versus-host disease pathways. HLA-C belongs to the HLA class I heavy chain paralogues and its genetic variation can influence the risk of HBV-related HCC development;<xref rid="b39-cmar-10-953" ref-type="bibr">39</xref> furthermore, HLA-C*15 is also an important host immunogenetic factor that negatively associates with hepatitis C virus viral load in chronic hepatitis C patients.<xref rid="b40-cmar-10-953" ref-type="bibr">40</xref></p><p>Studies of major histocompatibility complex class I and II gene polymorphisms demonstrate a risk factor for hepatitis virus and HCC. In the current study, our findings suggest that genetic variation in <italic>HLA-DPB1</italic>, <italic>HLA-DQB1</italic>, <italic>HLA-DRB1</italic>, and <italic>HLA-C</italic> were associated with TP53 expression status in HBV-related HCC. These results contribute to a better understanding of the heritability of <italic>HLA-DPB1</italic>, <italic>HLA-DQB1</italic>, <italic>HLA-DRB1</italic>, and <italic>HLA-C</italic> in HBV-related HCC and subsequently provide hypotheses to clarify their potential mechanisms in HBV and HCC genetic susceptibility.</p><p>In the remaining genes with candidate SNPs, we only found that <italic>IL6R</italic> and <italic>IL7R</italic> were associated with HCC among the previous studies, whereas associations between the other genes and human HCC have not been reported. IL6R encodes a subunit of the <italic>IL6R</italic> complex, and its dysregulation is related to the pathogenesis of many diseases, including cancer. A study by Deng et al revealed that the <italic>IL6R</italic>-rs6684439 T allele is associated with a lower susceptibility of HBV-related HCC in the Guangxi population,<xref rid="b41-cmar-10-953" ref-type="bibr">41</xref> whereas miR-451 plays a suppressive role in tumor angiogenesis via the regulation of the IL6R-signal transducer and activator of transcription 3-vascular endothelial growth factor signaling pathway.<xref rid="b42-cmar-10-953" ref-type="bibr">42</xref> Research by Midorikawa et al confirms that IL7R is downregulated in well-differentiated tumor tissue in HCC and can serve as a predictor gene of HCC dedifferentiation.<xref rid="b43-cmar-10-953" ref-type="bibr">43</xref> Our results contribute to a better understanding of genes associated with different HBV-related HCC subgroups.</p><p>Our association analysis demonstrated that seven genes with candidate SNPs were correlated to <italic>TP53</italic> at the HBV-related HCC mRNA level, whereas PPI networks showed that five genes with candidate SNPs were associated with TP53 via UBC through experiments. However, the GeneMANIA gene&#x02013;gene interaction networks showed complex co-expression networks among those genes, and all genes were directly or indirectly related to the <italic>TP53</italic> gene. In the present study, we confirmed that <italic>LGMN</italic> and <italic>TP53</italic> are positively correlated at the mRNA level in HBV-related HCC based on the GSE14520 data set, and our bioinformatics analysis by GeneMANIA also suggests that <italic>LGMN</italic> and <italic>TP53</italic> were co-expressed via the <italic>TAP1</italic> gene, whereas <italic>LGMN</italic> was also related to <italic>TP53</italic> via the <italic>UBC</italic> gene in the PPI networks that were constructed by STRING. A study by Murthy et al has reported that <italic>LGMN</italic> was significantly upregulated in tumor tissue and its low expression showed a better prognosis in colorectal cancer (CRC); meanwhile, it has a positive correlation with <italic>TP53</italic>.<xref rid="b44-cmar-10-953" ref-type="bibr">44</xref>
<italic>LGMN</italic> expression and its enzyme activity can also be regulated by <italic>TP53</italic>, and knockdown experiments suggest that <italic>LGMN</italic> and <italic>TP53</italic> have a positive correlation in HCT116 cells.<xref rid="b45-cmar-10-953" ref-type="bibr">45</xref> Our bioinformatics analysis also suggests that IL7R is associated with TP53 in GeneMANIA and PPI networks, and <italic>IL7</italic>/<italic>IL7R</italic> prevents apoptosis by regulating <italic>bcl-2</italic> expression and the <italic>TP53</italic> pathway in A549 and human bronchial epithelial cells.<xref rid="b46-cmar-10-953" ref-type="bibr">46</xref> Among the 10 candidate pathways, CAMs and cell communication pathways were the most common hypothetical biological mechanisms that involved the majority of candidate SNPs. CAMs play an important role in cell communication<xref rid="b47-cmar-10-953" ref-type="bibr">47</xref> and are associated with HCC diagnosis and survival prediction.<xref rid="b48-cmar-10-953" ref-type="bibr">48</xref>,<xref rid="b49-cmar-10-953" ref-type="bibr">49</xref> Our findings suggest a novel hypothetical biological mechanism between CAMs and TP53 expression status in HBV-related HCC.</p><p>Survival analysis in the current study indicates that the C allele of <italic>COL6A3</italic>-rs111231885 and <italic>COL6A3</italic>-rs113155945, and <italic>COL6A3</italic> block 4 CC haplotypes with TP53 negative status significantly decrease the risk of death in HBV-related HCC patients after hepatectomy. Previous studies have confirmed that high <italic>COL6A3</italic> expression was significantly associated with poor prognosis and its mutation can be used for survival prediction in CRC.<xref rid="b50-cmar-10-953" ref-type="bibr">50</xref>,<xref rid="b51-cmar-10-953" ref-type="bibr">51</xref> Furthermore, <italic>COL6A3</italic> was markedly upregulated in the tumor tissue of gastric cancer,<xref rid="b52-cmar-10-953" ref-type="bibr">52</xref>,<xref rid="b53-cmar-10-953" ref-type="bibr">53</xref> pancreatic cancer,<xref rid="b54-cmar-10-953" ref-type="bibr">54</xref>,<xref rid="b55-cmar-10-953" ref-type="bibr">55</xref> and CRC<xref rid="b50-cmar-10-953" ref-type="bibr">50</xref>,<xref rid="b56-cmar-10-953" ref-type="bibr">56</xref> and can serve as a potential diagnostic biomarker in these cancers. This evidence suggests that <italic>COL6A3</italic> may be a potential diagnosis and prognosis marker in CRC and may serve as an oncogene of CRC. Our findings demonstrate that several SNPs of <italic>COL6A3</italic> have a prediction value for HBV-related HCC prognosis and provide insight into the clinical utility of HBV-related HCC prognosis. Once validated, <italic>COL6A3</italic> may be used for prognosis prediction and decision-making in HCC management.</p><p>There were limitations in our study that need to be recognized. First, our study evaluates the association between TP53 expression status and candidate SNPs using the GWAS approach, and validates the association between the genes of the candidate SNPs and <italic>TP53</italic> using the Gene Expression Omnibus data set, GeneMANIA, and STRING bioinformatics tools that lack confirmation by in vivo and in vitro experiments. Second, all patients in the present study were exclusively from a Guangxi population of HBV-related HCC; therefore, in order to generalize our findings, additional external validation in cohorts from other ethnic populations is necessary to confirm our results.</p><p>Despite these limitations, our study is the first to explore the association between the SNPs and molecular pathways associated with TP53 expression status in HBV-related HCC by using the genome-wide association pathway analysis approach, and that might have etiology or clinical implications.</p></sec><sec><title>Conclusion</title><p>Genome-wide association pathway analysis in the current study identified 18 candidate SNPs and 10 candidate pathways that are associated with TP53 expression status in HBV-related HCC and generated five novel SNP-to-gene to pathway hypotheses. These results contribute to a better understanding of the heritability of HBV-related HCC in different TP53 expression subgroups and provide evidence for personalized treatment strategies of different TP53 expression subgroups in HBV-related HCC patients. Additional in vivo and in vitro experimental studies will be necessary to elucidate the role of these pathways in different TP53 expression subgroups of HBV-related HCC. Among these candidate SNPs, the C allele of <italic>COL6A3</italic>-rs111231885 and <italic>COL6A3</italic>-rs113155945, and <italic>COL6A3</italic> block 4 CC haplotypes with TP53 negative status may have protective effects in HBV-related HCC patients after hepatectomy and can serve as a potential prognostic biomarker. Further well-designed and larger sample size studies are needed to validate the associations between <italic>COL6A3</italic> genetic variation and HBV-related HCC prognosis.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported in part by the National Natural Science Foundation of China (no. 81560535, 81072321, 30760243, 30460143, and 30560133), 2009 Program for New Century Excellent Talents in University, Guangxi Natural Science Foundation (no. GuiKeGong 1104003A-7), Guangxi Health Ministry Medicine Grant (Key-Scientific Research-Grant Z201018), and Self-raised Scientific Research Fund of the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region (Z2016318). We also acknowledge the support offered by the National Key Clinical Specialty Programs (General Surgery and Oncology) and the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor (Guangxi Medical University), Ministry of Education, China. The authors thank Prof Minhao Peng, Lequn Li, Xiao Qin, Kaiyin Xiao, Xigang Chen, Bin Chen, Zhixiong Su, Ming Su, Zhang Wen, Jingning Lu, Ning Peng, and Hai Zhu, from the Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangxi Medical University, for providing part of the HCC samples for this study. Thanks also go to Prof Xue Qin (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) for providing patient&#x02019;s serum AFP assay results, and Prof Zengnan Mo (Center for Genomic and Personalized Medicine, Guangxi Medical University) for help in the GWAS analysis. We would like to acknowledge the assistance offered by researcher Jiaquan Li and Ying Gui from Guangxi Medical University for their contribution to specimen management. In addition, we also would like to acknowledge the contributors of GSE14520 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520</ext-link>) for sharing their data set on open access. We thank our reviewers for helpful comments on this article.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cmar-10-953"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Baade</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Cancer statistics in China, 2015</article-title><source>CA Cancer J Clin</source><year>2016</year><volume>66</volume><issue>2</issue><fpage>115</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">26808342</pub-id></element-citation></ref><ref id="b2-cmar-10-953"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cancer survival in China, 2003&#x02013;2005: a population-based study</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><issue>8</issue><fpage>1921</fpage><lpage>1930</lpage><pub-id pub-id-type="pmid">25242378</pub-id></element-citation></ref><ref id="b3-cmar-10-953"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Rudolph</surname><given-names>KL</given-names></name></person-group><article-title>Hepatocellular carcinoma: epidemiology and molecular carcinogenesis</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><issue>7</issue><fpage>2557</fpage><lpage>2576</lpage><pub-id pub-id-type="pmid">17570226</pub-id></element-citation></ref><ref id="b4-cmar-10-953"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweitzer</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>J</given-names></name><name><surname>Mikolajczyk</surname><given-names>RT</given-names></name><name><surname>Krause</surname><given-names>G</given-names></name><name><surname>Ott</surname><given-names>JJ</given-names></name></person-group><article-title>Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</article-title><source>Lancet</source><year>2015</year><volume>386</volume><issue>10003</issue><fpage>1546</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">26231459</pub-id></element-citation></ref><ref id="b5-cmar-10-953"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e83465</fpage><pub-id pub-id-type="pmid">24391771</pub-id></element-citation></ref><ref id="b6-cmar-10-953"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name><name><surname>Peng</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma</article-title><source>Cancer Lett</source><year>2008</year><volume>263</volume><issue>2</issue><fpage>212</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">18280645</pub-id></element-citation></ref><ref id="b7-cmar-10-953"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><etal/></person-group><article-title>XRCC1 rs25487 genetic variant and TP53 mutation at codon 249 predict clinical outcomes of hepatitis B virusrelated hepatocellular carcinoma after hepatectomy: a cohort study for 10 years&#x02019; follow up</article-title><source>Hepatol Res</source><year>2016</year><volume>46</volume><issue>8</issue><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">26519348</pub-id></element-citation></ref><ref id="b8-cmar-10-953"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>MC</given-names></name><name><surname>Umbach</surname><given-names>DM</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>London</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>ZQ</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name></person-group><article-title>Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People&#x02019;s Republic of China, and a meta-analysis of existing studies</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2001</year><volume>10</volume><issue>6</issue><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">11401911</pub-id></element-citation></ref><ref id="b9-cmar-10-953"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>LN</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>ZS</given-names></name><etal/></person-group><article-title>The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure</article-title><source>Liver Int</source><year>2015</year><volume>35</volume><issue>3</issue><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">24461059</pub-id></element-citation></ref><ref id="b10-cmar-10-953"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>XD</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>HD</given-names></name><name><surname>Yao</surname><given-names>JG</given-names></name><name><surname>Qu</surname><given-names>DY</given-names></name><name><surname>Lu</surname><given-names>YL</given-names></name></person-group><article-title>Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China</article-title><source>Mol Carcinog</source><year>2008</year><volume>47</volume><issue>4</issue><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">17849423</pub-id></element-citation></ref><ref id="b11-cmar-10-953"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farazi</surname><given-names>PA</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><article-title>Hepatocellular carcinoma pathogenesis: from genes to environment</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><issue>9</issue><fpage>674</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">16929323</pub-id></element-citation></ref><ref id="b12-cmar-10-953"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2016</year><volume>2</volume><fpage>16018</fpage><pub-id pub-id-type="pmid">27158749</pub-id></element-citation></ref><ref id="b13-cmar-10-953"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolio</surname><given-names>TA</given-names></name></person-group><article-title>Genomewide association studies and assessment of the risk of disease</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>2</issue><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">20647212</pub-id></element-citation></ref><ref id="b14-cmar-10-953"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>ICSNPathway: identify candidate causal SNPs and pathways from genome-wide association study by one analytical framework</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>Web Server issue</issue><fpage>W437</fpage><lpage>W443</lpage><pub-id pub-id-type="pmid">21622953</pub-id></element-citation></ref><ref id="b15-cmar-10-953"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Genome-wide association study identified PLCE1-rs2797992 and EGFR-rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi</article-title><source>Am J Transl Res</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>1799</fpage><lpage>1812</lpage><pub-id pub-id-type="pmid">27186304</pub-id></element-citation></ref><ref id="b16-cmar-10-953"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><issue>2</issue><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></element-citation></ref><ref id="b17-cmar-10-953"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>AD</given-names></name><name><surname>Handsaker</surname><given-names>RE</given-names></name><name><surname>Pulit</surname><given-names>SL</given-names></name><name><surname>Nizzari</surname><given-names>MM</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>CJ</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name></person-group><article-title>SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><issue>24</issue><fpage>2938</fpage><lpage>2939</lpage><pub-id pub-id-type="pmid">18974171</pub-id></element-citation></ref><ref id="b18-cmar-10-953"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roessler</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>EL</given-names></name><name><surname>Budhu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><issue>4</issue><fpage>957</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">22202459</pub-id></element-citation></ref><ref id="b19-cmar-10-953"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roessler</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>HL</given-names></name><name><surname>Budhu</surname><given-names>A</given-names></name><etal/></person-group><article-title>A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>24</issue><fpage>10202</fpage><lpage>10212</lpage><pub-id pub-id-type="pmid">21159642</pub-id></element-citation></ref><ref id="b20-cmar-10-953"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warde-Farley</surname><given-names>D</given-names></name><name><surname>Donaldson</surname><given-names>SL</given-names></name><name><surname>Comes</surname><given-names>O</given-names></name><etal/></person-group><article-title>The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><issue>Web Server issue</issue><fpage>W214</fpage><lpage>W220</lpage><pub-id pub-id-type="pmid">20576703</pub-id></element-citation></ref><ref id="b21-cmar-10-953"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafavi</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Warde-Farley</surname><given-names>D</given-names></name><name><surname>Grouios</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>Q</given-names></name></person-group><article-title>GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><issue>Suppl 1</issue><fpage>S4</fpage></element-citation></ref><ref id="b22-cmar-10-953"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><etal/></person-group><article-title>STRING v10: protein&#x02013;protein interaction networks, integrated over the tree of life</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>Database issue</issue><fpage>D447</fpage><lpage>D452</lpage><pub-id pub-id-type="pmid">25352553</pub-id></element-citation></ref><ref id="b23-cmar-10-953"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Huynen</surname><given-names>M</given-names></name><name><surname>Jaeggi</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Snel</surname><given-names>B</given-names></name></person-group><article-title>STRING: a database of predicted functional associations between proteins</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><issue>1</issue><fpage>258</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">12519996</pub-id></element-citation></ref><ref id="b24-cmar-10-953"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanan</surname><given-names>VK</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>JH</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name></person-group><article-title>Pathway analysis of genomic data: concepts, methods, and prospects for future development</article-title><source>Trends Genet</source><year>2012</year><volume>28</volume><issue>7</issue><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">22480918</pub-id></element-citation></ref><ref id="b25-cmar-10-953"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbers</surname><given-names>CC</given-names></name><name><surname>van Eijk</surname><given-names>KR</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><etal/></person-group><article-title>Using genome-wide pathway analysis to unravel the etiology of complex diseases</article-title><source>Genet Epidemiol</source><year>2009</year><volume>33</volume><issue>5</issue><fpage>419</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">19235186</pub-id></element-citation></ref><ref id="b26-cmar-10-953"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posuwan</surname><given-names>N</given-names></name><name><surname>Payungporn</surname><given-names>S</given-names></name><name><surname>Tangkijvanich</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in Thai population</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e86007</fpage><pub-id pub-id-type="pmid">24465836</pub-id></element-citation></ref><ref id="b27-cmar-10-953"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>A genome-wide association study identified new variants associated with the risk of chronic hepatitis B</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><issue>20</issue><fpage>4233</fpage><lpage>4238</lpage><pub-id pub-id-type="pmid">23760081</pub-id></element-citation></ref><ref id="b28-cmar-10-953"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>PT</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name></person-group><article-title>HLA class II alleles in Chinese patients with hepatocellular carcinoma</article-title><source>Liver</source><year>2001</year><volume>21</volume><issue>2</issue><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">11318984</pub-id></element-citation></ref><ref id="b29-cmar-10-953"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akgollu</surname><given-names>E</given-names></name><name><surname>Bilgin</surname><given-names>R</given-names></name><name><surname>Akkiz</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between chronic hepatitis B virus infection and HLA-DP gene polymorphisms in the Turkish population</article-title><source>Virus Res</source><year>2017</year><volume>232</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">28119119</pub-id></element-citation></ref><ref id="b30-cmar-10-953"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Cheng</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>14933</fpage><pub-id pub-id-type="pmid">26462556</pub-id></element-citation></ref><ref id="b31-cmar-10-953"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name></person-group><article-title>Association of polymorphisms of human leucocyte antigen-DQA1 and DQB1 alleles with chronic hepatitis B virus infection, liver cirrhosis and hepatocellular carcinoma in Chinese</article-title><source>Int J Immunogenet</source><year>2007</year><volume>34</volume><issue>5</issue><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">17845309</pub-id></element-citation></ref><ref id="b32-cmar-10-953"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Chennawi</surname><given-names>FA</given-names></name><name><surname>Auf</surname><given-names>FA</given-names></name><name><surname>Metwally</surname><given-names>SS</given-names></name><name><surname>Mosaad</surname><given-names>YM</given-names></name><name><surname>El-Wahab</surname><given-names>MA</given-names></name><name><surname>Tawhid</surname><given-names>ZE</given-names></name></person-group><article-title>HLA-class II alleles in Egyptian patients with hepatocellular carcinoma</article-title><source>Immunol Invest</source><year>2008</year><volume>37</volume><issue>7</issue><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">18821214</pub-id></element-citation></ref><ref id="b33-cmar-10-953"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Re</surname><given-names>V</given-names></name><name><surname>Caggiari</surname><given-names>L</given-names></name><name><surname>Talamini</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles</article-title><source>Hum Immunol</source><year>2004</year><volume>65</volume><issue>11</issue><fpage>1397</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">15556690</pub-id></element-citation></ref><ref id="b34-cmar-10-953"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><etal/></person-group><article-title>Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2016</year><volume>40</volume><issue>6</issue><fpage>739</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">27288300</pub-id></element-citation></ref><ref id="b35-cmar-10-953"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>49</issue><fpage>80935</fpage><lpage>80942</lpage><pub-id pub-id-type="pmid">27821814</pub-id></element-citation></ref><ref id="b36-cmar-10-953"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>DK</given-names></name><name><surname>Ma</surname><given-names>XP</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genetic variations in STAT4, C2, HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>16278</fpage><pub-id pub-id-type="pmid">26538132</pub-id></element-citation></ref><ref id="b37-cmar-10-953"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers</article-title><source>PLoS Genet</source><year>2012</year><volume>8</volume><issue>7</issue><fpage>e1002791</fpage><pub-id pub-id-type="pmid">22807686</pub-id></element-citation></ref><ref id="b38-cmar-10-953"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>YJ</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Relationship of HLA-DRB1 alleles with hepatocellular carcinoma development in chronic hepatitis B patients</article-title><source>J Clin Gastroenterol</source><year>2012</year><volume>46</volume><issue>5</issue><fpage>420</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">22499074</pub-id></element-citation></ref><ref id="b39-cmar-10-953"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>N</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group><article-title>KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>10</issue><fpage>e25682</fpage><pub-id pub-id-type="pmid">21998681</pub-id></element-citation></ref><ref id="b40-cmar-10-953"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>KC</given-names></name><name><surname>Tseng</surname><given-names>CW</given-names></name><name><surname>Hsieh</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan</article-title><source>Hum Immunol</source><year>2013</year><volume>74</volume><issue>8</issue><fpage>978</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">23628398</pub-id></element-citation></ref><ref id="b41-cmar-10-953"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Susceptibility to hepatocellular carcinoma in the Chinese population: associations with interleukin-6 receptor polymorphism</article-title><source>Tumour Biol</source><year>2014</year><volume>35</volume><issue>7</issue><fpage>6383</fpage><lpage>6388</lpage><pub-id pub-id-type="pmid">24668548</pub-id></element-citation></ref><ref id="b42-cmar-10-953"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway</article-title><source>Oncol Rep</source><year>2016</year><volume>36</volume><issue>3</issue><fpage>1385</fpage><lpage>1392</lpage><pub-id pub-id-type="pmid">27461244</pub-id></element-citation></ref><ref id="b43-cmar-10-953"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midorikawa</surname><given-names>Y</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis</article-title><source>Jpn J Cancer Res</source><year>2002</year><volume>93</volume><issue>6</issue><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">12079511</pub-id></element-citation></ref><ref id="b44-cmar-10-953"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>RV</given-names></name><name><surname>Arbman</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Roodman</surname><given-names>GD</given-names></name><name><surname>Sun</surname><given-names>XF</given-names></name></person-group><article-title>Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>6</issue><fpage>2293</fpage><lpage>2299</lpage><pub-id pub-id-type="pmid">15788679</pub-id></element-citation></ref><ref id="b45-cmar-10-953"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamane</surname><given-names>T</given-names></name><name><surname>Murao</surname><given-names>S</given-names></name><name><surname>Kato-Ose</surname><given-names>I</given-names></name><etal/></person-group><article-title>Transcriptional regulation of the legumain gene by p53 in HCT116 cells</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>438</volume><issue>4</issue><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">23942113</pub-id></element-citation></ref><ref id="b46-cmar-10-953"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZH</given-names></name><name><surname>Wang</surname><given-names>MH</given-names></name><name><surname>Ren</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells</article-title><source>Int J Clin Exp Pathol</source><year>2014</year><volume>7</volume><issue>3</issue><fpage>870</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">24695377</pub-id></element-citation></ref><ref id="b47-cmar-10-953"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linhardt</surname><given-names>RJ</given-names></name><name><surname>Toida</surname><given-names>T</given-names></name></person-group><article-title>Role of glycosaminoglycans in cellular communication</article-title><source>Acc Chem Res</source><year>2004</year><volume>37</volume><issue>7</issue><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">15260505</pub-id></element-citation></ref><ref id="b48-cmar-10-953"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliaz</surname><given-names>R</given-names></name><name><surname>Akyuz</surname><given-names>U</given-names></name><name><surname>Tekin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma</article-title><source>Arab J Gastroenterol</source><year>2016</year><volume>17</volume><issue>4</issue><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">27916547</pub-id></element-citation></ref><ref id="b49-cmar-10-953"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Minemura</surname><given-names>M</given-names></name><name><surname>Tsukishiro</surname><given-names>T</given-names></name><etal/></person-group><article-title>Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis</article-title><source>Hepatology</source><year>1995</year><volume>22</volume><issue>2</issue><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">7543436</pub-id></element-citation></ref><ref id="b50-cmar-10-953"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>SX</given-names></name><etal/></person-group><article-title>Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><issue>30</issue><fpage>29929</fpage><lpage>29946</lpage><pub-id pub-id-type="pmid">26338966</pub-id></element-citation></ref><ref id="b51-cmar-10-953"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>WK</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer</article-title><source>Gut</source><year>2015</year><volume>64</volume><issue>4</issue><fpage>636</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">24951259</pub-id></element-citation></ref><ref id="b52-cmar-10-953"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Overexpression of collagen VI &#x003b1;3 in gastric cancer</article-title><source>Oncol Lett</source><year>2014</year><volume>7</volume><issue>5</issue><fpage>1537</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">24765172</pub-id></element-citation></ref><ref id="b53-cmar-10-953"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>Identification of key genes associated with gastric cancer based on DNA microarray data</article-title><source>Oncol Lett</source><year>2016</year><volume>11</volume><issue>1</issue><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">26870242</pub-id></element-citation></ref><ref id="b54-cmar-10-953"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arafat</surname><given-names>H</given-names></name><name><surname>Lazar</surname><given-names>M</given-names></name><name><surname>Salem</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer</article-title><source>Surgery</source><year>2011</year><volume>150</volume><issue>2</issue><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">21719059</pub-id></element-citation></ref><ref id="b55-cmar-10-953"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Axell-House</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma</article-title><source>J Gastrointest Surg</source><year>2014</year><volume>18</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24002763</pub-id></element-citation></ref><ref id="b56-cmar-10-953"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snezhkina</surname><given-names>AV</given-names></name><name><surname>Krasnov</surname><given-names>GS</given-names></name><name><surname>Zaretsky</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer</article-title><source>BMC Genomics</source><year>2016</year><volume>17</volume><issue>Suppl 14</issue><fpage>1011</fpage><pub-id pub-id-type="pmid">28105922</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cmar-10-953" position="float"><label>Figure 1</label><caption><p>Haplotype association of the candidate SNPs and co-expression heat map for the <italic>TP53</italic> gene and corresponding genes of the candidate SNPs.</p><p><bold>Notes:</bold> (<bold>A</bold>) Patterns of LD plots for 16 candidate SNPs. (<bold>B</bold>) Co-expression heat map between TP53 and corresponding genes of the candidate SNPs.</p><p><bold>Abbreviations:</bold> SNP, single nucleotide polymorphism; TP53, tumor protein p53; LD, linkage disequilibrium.</p></caption><graphic xlink:href="cmar-10-953Fig1"/></fig><fig id="f2-cmar-10-953" position="float"><label>Figure 2</label><caption><p>Gene&#x02013;gene and protein&#x02013;protein interaction networks.</p><p><bold>Notes:</bold> (<bold>A</bold>) Gene&#x02013;gene interaction networks constructed by GeneMANIA. (<bold>B</bold>) Protein&#x02013;protein interaction networks constructed by STRING.</p><p><bold>Abbreviations:</bold> GeneMANIA, Gene Multiple Association Network Integration Algorithm; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; TP53, tumor protein p53; UBC, ubiquitin C; <italic>HLA-DPB1</italic>, major histocompatibility complex, class II, DP beta 1; <italic>HLA-DQB1</italic>, major histocompatibility complex, class II, DQ beta 1; <italic>HLA-DRB1</italic>, major histocompatibility complex, class II, DR beta 1; <italic>HLA-C</italic>, major histocompatibility complex, class I, C; <italic>COL6A3</italic>, collagen type VI alpha 3 chain; <italic>DSG3</italic>, desmoglein 3; <italic>KRT32</italic>, keratin 32; <italic>KRT35</italic>, keratin 35; <italic>KRT36</italic>, keratin 36; <italic>LGMN</italic>, legumain; <italic>IL6R</italic>, interleukin 6 receptor; <italic>IL7R</italic>, interleukin 7 receptor.</p></caption><graphic xlink:href="cmar-10-953Fig2"/></fig><fig id="f3-cmar-10-953" position="float"><label>Figure 3</label><caption><p>Regional LD plots of block 2 (<italic>HLA-DQB1</italic>).</p><p><bold>Notes:</bold> Regional LD plots of (<bold>A</bold>) <italic>HLA-DQB1</italic>-rs1049056, (<bold>B</bold>) <italic>HLA-DQB1</italic>-rs1049059, (<bold>C</bold>) <italic>HLA-DQB1</italic>-rs1049060, and (<bold>D</bold>) <italic>HLA-DQB1</italic>-rs1130399.</p><p><bold>Abbreviations:</bold> LD, linkage disequilibrium; HLA-DQB1, major histocompatibility complex, class II, DQ beta 1; CHB, chronic hepatitis B.</p></caption><graphic xlink:href="cmar-10-953Fig3"/></fig><fig id="f4-cmar-10-953" position="float"><label>Figure 4</label><caption><p>Regional LD plots of block 3 (<italic>KRT35</italic> and <italic>KRT36</italic>) and block 4 (<italic>COL6A3</italic>).</p><p><bold>Notes:</bold> Regional LD plots of (<bold>A</bold>) <italic>KRT35</italic>-rs743686, (<bold>B</bold>) <italic>KRT36</italic>-rs2301354, (<bold>C</bold>) <italic>COL6A3</italic>-rs111231885, and (<bold>D</bold>) <italic>COL6A3</italic>-rs113155945.</p><p><bold>Abbreviations:</bold> LD, linkage disequilibrium; KRT35, keratin 35; KRT36, keratin 36; COL6A3, collagen type VI alpha 3 chain.</p></caption><graphic xlink:href="cmar-10-953Fig4"/></fig><fig id="f5-cmar-10-953" position="float"><label>Figure 5</label><caption><p>Survival curves of different haplotypes.</p><p><bold>Notes:</bold> OS stratified by (<bold>A</bold>) block 1 haplotypes, (<bold>B</bold>) block 2 haplotypes, (<bold>C</bold>) block 3 haplotypes, (<bold>D</bold>) block 4 haplotypes.</p><p><bold>Abbreviations:</bold> OS, overall survival.</p></caption><graphic xlink:href="cmar-10-953Fig5"/></fig><fig id="f6-cmar-10-953" position="float"><label>Figure 6</label><caption><p>Joint effects survival analysis of different haplotypes and TP53 expression status.</p><p><bold>Notes:</bold> OS stratified by (<bold>A</bold>) block 1 haplotypes and TP53 expression status, (<bold>B</bold>) block 2 haplotypes and TP53 expression status, (<bold>C</bold>) block 3 haplotypes and TP53 expression status, (<bold>D</bold>) block 4 haplotypes and TP53 expression status.</p><p><bold>Abbreviations:</bold> OS, overall survival; TP53, tumor protein p53.</p></caption><graphic xlink:href="cmar-10-953Fig6"/></fig><table-wrap id="t1-cmar-10-953" position="float"><label>Table 1</label><caption><p>Candidate SNPs identified from ICSNPathway analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Candidate SNP</th><th valign="top" align="left" rowspan="1" colspan="1">Functional class</th><th valign="top" align="left" rowspan="1" colspan="1">Gene</th><th valign="top" align="left" rowspan="1" colspan="1">Candidate pathway<xref ref-type="table-fn" rid="tfn1-cmar-10-953">a</xref></th><th valign="top" align="left" rowspan="1" colspan="1">&#x02212;log10(<italic>P</italic>)<xref ref-type="table-fn" rid="tfn2-cmar-10-953">b</xref></th><th valign="top" align="left" rowspan="1" colspan="1">In LD with</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>r</italic><sup>2</sup></th><th valign="top" align="left" rowspan="1" colspan="1">D&#x02019;</th><th valign="top" align="left" rowspan="1" colspan="1">&#x02212;log10(<italic>P</italic>)<xref ref-type="table-fn" rid="tfn3-cmar-10-953">c</xref> in original GWAS</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1042153</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DPB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.45</td><td valign="top" align="left" rowspan="1" colspan="1">rs1042153</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.45</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1130399</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DQB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">3.153</td><td valign="top" align="left" rowspan="1" colspan="1">rs1130399</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3.153</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1049056</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DQB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.433</td><td valign="top" align="left" rowspan="1" colspan="1">rs1049056</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.433</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1049059</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DQB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.357</td><td valign="top" align="left" rowspan="1" colspan="1">rs1049059</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.357</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1049060</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DQB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.467</td><td valign="top" align="left" rowspan="1" colspan="1">rs1049060</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.467</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs35445101</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-DRB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1,2,3,4,5,7,8,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">3.591</td><td valign="top" align="left" rowspan="1" colspan="1">rs35445101</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3.591</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1131096</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-C</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.097</td><td valign="top" align="left" rowspan="1" colspan="1">rs1131096</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.097</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs1130838</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HLA-C</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3,4,5,7,9,10</td><td valign="top" align="left" rowspan="1" colspan="1">2.267</td><td valign="top" align="left" rowspan="1" colspan="1">rs1130838</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.267</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs111231885</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>COL6A3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">2.541</td><td valign="top" align="left" rowspan="1" colspan="1">rs111231885</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.541</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs113155945</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>COL6A3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">2.044</td><td valign="top" align="left" rowspan="1" colspan="1">rs113155945</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.044</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs16961975</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding (deleterious)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>DSG3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">2.12</td><td valign="top" align="left" rowspan="1" colspan="1">rs16961975</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs3744786</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KRT32</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">rs2301354</td><td valign="top" align="left" rowspan="1" colspan="1">0.847</td><td valign="top" align="left" rowspan="1" colspan="1">0.945</td><td valign="top" align="left" rowspan="1" colspan="1">3.583</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs2071601</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding (deleterious)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KRT35</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">rs2301354</td><td valign="top" align="left" rowspan="1" colspan="1">0.901</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">3.583</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs743686</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding (deleterious)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KRT35</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">3.209</td><td valign="top" align="left" rowspan="1" colspan="1">rs743686</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3.209</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs2301354</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding (deleterious)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KRT36</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">3.583</td><td valign="top" align="left" rowspan="1" colspan="1">rs2301354</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3.583</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs118128989</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>LGMN</italic></td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">2.084</td><td valign="top" align="left" rowspan="1" colspan="1">rs118128989</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.084</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs2228145</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>IL6R</italic></td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2.081</td><td valign="top" align="left" rowspan="1" colspan="1">rs2228145</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.081</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">rs6897932</td><td valign="top" align="left" rowspan="1" colspan="1">non_synonymous_coding</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>IL7R</italic></td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2.004</td><td valign="top" align="left" rowspan="1" colspan="1">rs6897932</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2.004</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-cmar-10-953"><label>a</label><p>The number indicates the index of pathways (listed in <xref ref-type="table" rid="t2-cmar-10-953">Table 2</xref>), which are ranked by their statistical significance (FDR).</p></fn><fn id="tfn2-cmar-10-953"><label>b</label><p>&#x02212;log<sub>10</sub>(<italic>P</italic>) for candidate SNP in original GWAS. &#x0201c;&#x02013;&#x0201d; denotes that this SNP is not represented in the original GWAS.</p></fn><fn id="tfn3-cmar-10-953"><label>c</label><p>&#x02212;log<sub>10</sub>(<italic>P</italic>) for the SNP (which candidate SNP is in LD with) in original GWAS.</p></fn><fn id="tfn4-cmar-10-953"><p><bold>Abbreviations:</bold> SNP, single nucleotide polymorphism; ICSNPathway, Identify candidate Causal SNPs and Pathways; LD, linkage disequilibrium; GWAS, genome-wide association studies; <italic>HLA-DPB1</italic>, major histocompatibility complex, class II, DP beta 1; <italic>HLA-DQB1</italic>, major histocompatibility complex, class II, DQ beta 1; <italic>HLA-DRB1</italic>, major histocompatibility complex, class II, DR beta 1; <italic>HLA-C</italic>, major histocompatibility complex, class I, C; <italic>COL6A3</italic>, collagen type VI alpha 3 chain; <italic>DSG3</italic>, desmoglein 3; <italic>KRT32</italic>, keratin 32; <italic>KRT35</italic>, keratin 35; <italic>KRT36</italic>, keratin 36; <italic>LGMN</italic>, legumain; <italic>IL6R</italic>, interleukin 6 receptor; <italic>IL7R</italic>, interleukin 7 receptor; FDR, false discovery rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cmar-10-953" position="float"><label>Table 2</label><caption><p>Candidate pathways identified from ICSNPathway analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Index</th><th valign="top" align="left" rowspan="1" colspan="1">Candidate pathway</th><th valign="top" align="left" rowspan="1" colspan="1">Description</th><th valign="top" align="left" rowspan="1" colspan="1">Nominal <italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">hsa05310</td><td valign="top" align="left" rowspan="1" colspan="1">Asthma</td><td valign="top" align="left" rowspan="1" colspan="1">0.005</td><td valign="top" align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">hsa05322</td><td valign="top" align="left" rowspan="1" colspan="1">Systemic lupus erythematosus</td><td valign="top" align="left" rowspan="1" colspan="1">0.005</td><td valign="top" align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">hsa04514</td><td valign="top" align="left" rowspan="1" colspan="1">CAMs</td><td valign="top" align="left" rowspan="1" colspan="1">0.034</td><td valign="top" align="left" rowspan="1" colspan="1">0.056</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">hsa05320</td><td valign="top" align="left" rowspan="1" colspan="1">Autoimmune thyroid disease</td><td valign="top" align="left" rowspan="1" colspan="1">0.028</td><td valign="top" align="left" rowspan="1" colspan="1">0.058</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">hsa05330</td><td valign="top" align="left" rowspan="1" colspan="1">Allograft rejection</td><td valign="top" align="left" rowspan="1" colspan="1">0.028</td><td valign="top" align="left" rowspan="1" colspan="1">0.058</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">hsa01430</td><td valign="top" align="left" rowspan="1" colspan="1">Cell communication</td><td valign="top" align="left" rowspan="1" colspan="1">0.024</td><td valign="top" align="left" rowspan="1" colspan="1">0.058</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">hsa04612</td><td valign="top" align="left" rowspan="1" colspan="1">Antigen processing and presentation</td><td valign="top" align="left" rowspan="1" colspan="1">0.041</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">hsa04640</td><td valign="top" align="left" rowspan="1" colspan="1">Hematopoietic cell lineage</td><td valign="top" align="left" rowspan="1" colspan="1">0.009</td><td valign="top" align="left" rowspan="1" colspan="1">0.069</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">hsa04940</td><td valign="top" align="left" rowspan="1" colspan="1">Type I diabetes mellitus</td><td valign="top" align="left" rowspan="1" colspan="1">0.032</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">hsa05332</td><td valign="top" align="left" rowspan="1" colspan="1">Graft-versus-host disease</td><td valign="top" align="left" rowspan="1" colspan="1">0.032</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-cmar-10-953"><p><bold>Abbreviations:</bold> FDR, false discovery rate; CAMs, cell adhesion molecules; ICSNPathway, Identify candidate Causal SNPs and Pathways.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cmar-10-953" position="float"><label>Table 3</label><caption><p>Haplotype distribution of the candidate SNPs in patients with different TP53 expression status</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Haplotypes</th><th valign="top" align="left" rowspan="1" colspan="1">TP53 negative (2n=308)</th><th valign="top" align="left" rowspan="1" colspan="1">TP53 positive (2n=466)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude OR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude <italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted <italic>P</italic>-value<xref ref-type="table-fn" rid="tfn6-cmar-10-953">a</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC</td><td valign="top" align="left" rowspan="1" colspan="1">229</td><td valign="top" align="left" rowspan="1" colspan="1">387</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GT</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">0.592 (0.416&#x02013;0.841)</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.622 (0.432&#x02013;0.895)</td><td valign="top" align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 2</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AGAGA</td><td valign="top" align="left" rowspan="1" colspan="1">118</td><td valign="top" align="left" rowspan="1" colspan="1">238</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AGTCC</td><td valign="top" align="left" rowspan="1" colspan="1">116</td><td valign="top" align="left" rowspan="1" colspan="1">167</td><td valign="top" align="left" rowspan="1" colspan="1">0.714 (0.516&#x02013;0.987)</td><td valign="top" align="left" rowspan="1" colspan="1">0.041</td><td valign="top" align="left" rowspan="1" colspan="1">0.696 (0.494&#x02013;0.980)</td><td valign="top" align="left" rowspan="1" colspan="1">0.038</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GATCC+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">74</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">0.409 (0.273&#x02013;0.612)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.395 (0.259&#x02013;0.603)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 3</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AG</td><td valign="top" align="left" rowspan="1" colspan="1">156</td><td valign="top" align="left" rowspan="1" colspan="1">291</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GA+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">152</td><td valign="top" align="left" rowspan="1" colspan="1">175</td><td valign="top" align="left" rowspan="1" colspan="1">0.617 (0.461&#x02013;0.826)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.582 (0.427&#x02013;0.792)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 4</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CC</td><td valign="top" align="left" rowspan="1" colspan="1">279</td><td valign="top" align="left" rowspan="1" colspan="1">446</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TT+other</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">0.431 (0.239&#x02013;0.777)</td><td valign="top" align="left" rowspan="1" colspan="1">0.005</td><td valign="top" align="left" rowspan="1" colspan="1">0.376 (0.201&#x02013;0.703)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn6-cmar-10-953"><label>a</label><p>Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.</p></fn><fn id="tfn7-cmar-10-953"><p><bold>Abbreviations:</bold> SNP, single nucleotide polymorphism; TP53, tumor protein p53; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-cmar-10-953" position="float"><label>Table 4</label><caption><p>Clinicopathological characteristics of patients with HBV-related HCC after data quality control</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Variable</th><th colspan="4" valign="top" align="left" rowspan="1">GWAS
<hr/></th><th colspan="4" valign="top" align="left" rowspan="1">Survival analysis
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">TP53 negative (n=154)</th><th valign="top" align="left" rowspan="1" colspan="1">TP53 positive (n=233)</th><th valign="top" align="left" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Patients (n=387)</th><th valign="top" align="left" rowspan="1" colspan="1">MST (months)</th><th valign="top" align="left" rowspan="1" colspan="1">HR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Log-rank <italic>P</italic></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.313</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02264;60</td><td valign="top" align="left" rowspan="1" colspan="1">133</td><td valign="top" align="left" rowspan="1" colspan="1">211</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">344</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;60</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="left" rowspan="1" colspan="1">0.66 (0.35&#x02013;1.247)</td><td valign="top" align="left" rowspan="1" colspan="1">0.201</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.268 (0.795&#x02013;2.023)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.563</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">141</td><td valign="top" align="left" rowspan="1" colspan="1">207</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">348</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">0.734 (0.365&#x02013;1.477)</td><td valign="top" align="left" rowspan="1" colspan="1">0.386</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">42</td><td valign="top" align="left" rowspan="1" colspan="1">0.856 (0.504&#x02013;1.455)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.837</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Han</td><td valign="top" align="left" rowspan="1" colspan="1">103</td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">245</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Minority</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">91</td><td valign="top" align="left" rowspan="1" colspan="1">1.294 (0.845&#x02013;1.983)</td><td valign="top" align="left" rowspan="1" colspan="1">0.236</td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">0.968 (0.711&#x02013;1.318)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.933</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02264;25</td><td valign="top" align="left" rowspan="1" colspan="1">121</td><td valign="top" align="left" rowspan="1" colspan="1">181</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">302</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;25</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">52</td><td valign="top" align="left" rowspan="1" colspan="1">1.053 (0.643&#x02013;1.725)</td><td valign="top" align="left" rowspan="1" colspan="1">0.836</td><td valign="top" align="left" rowspan="1" colspan="1">85</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1">0.985 (0.694&#x02013;1.399)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">97</td><td valign="top" align="left" rowspan="1" colspan="1">147</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">244</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Ever</td><td valign="top" align="left" rowspan="1" colspan="1">57</td><td valign="top" align="left" rowspan="1" colspan="1">86</td><td valign="top" align="left" rowspan="1" colspan="1">0.996 (0.653&#x02013;1.518)</td><td valign="top" align="left" rowspan="1" colspan="1">0.984</td><td valign="top" align="left" rowspan="1" colspan="1">143</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">1.342 (0.992&#x02013;1.816)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Drinking status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.153</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">91</td><td valign="top" align="left" rowspan="1" colspan="1">134</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">225</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Ever</td><td valign="top" align="left" rowspan="1" colspan="1">63</td><td valign="top" align="left" rowspan="1" colspan="1">99</td><td valign="top" align="left" rowspan="1" colspan="1">1.067 (0.706&#x02013;1.613)</td><td valign="top" align="left" rowspan="1" colspan="1">0.758</td><td valign="top" align="left" rowspan="1" colspan="1">162</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.239 (0.921&#x02013;1.666)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Child&#x02013;Pugh<xref ref-type="table-fn" rid="tfn8-cmar-10-953">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;A</td><td valign="top" align="left" rowspan="1" colspan="1">116</td><td valign="top" align="left" rowspan="1" colspan="1">189</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">305</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;B</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">0.658 (0.374&#x02013;1.156)</td><td valign="top" align="left" rowspan="1" colspan="1">0.146</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">1.665 (1.131&#x02013;2.452)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.117</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">88</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">206</td><td valign="top" align="left" rowspan="1" colspan="1">0.645 (0.316&#x02013;1.315)</td><td valign="top" align="left" rowspan="1" colspan="1">0.228</td><td valign="top" align="left" rowspan="1" colspan="1">348</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1.503 (0.897&#x02013;2.518)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Radical resection<xref ref-type="table-fn" rid="tfn9-cmar-10-953">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.095</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">82</td><td valign="top" align="left" rowspan="1" colspan="1">133</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">215</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">94</td><td valign="top" align="left" rowspan="1" colspan="1">0.865 (0.57&#x02013;1.313)</td><td valign="top" align="left" rowspan="1" colspan="1">0.496</td><td valign="top" align="left" rowspan="1" colspan="1">161</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.286 (0.955&#x02013;1.733)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Portal hypertension<xref ref-type="table-fn" rid="tfn10-cmar-10-953">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.347</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">69</td><td valign="top" align="left" rowspan="1" colspan="1">124</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">193</td><td valign="top" align="left" rowspan="1" colspan="1">52</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1">87</td><td valign="top" align="left" rowspan="1" colspan="1">0.645 (0.421&#x02013;0.989)</td><td valign="top" align="left" rowspan="1" colspan="1">0.044</td><td valign="top" align="left" rowspan="1" colspan="1">162</td><td valign="top" align="left" rowspan="1" colspan="1">42</td><td valign="top" align="left" rowspan="1" colspan="1">1.163 (0.847&#x02013;1.598)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pathological grade<xref ref-type="table-fn" rid="tfn11-cmar-10-953">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.665</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Well differentiated</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderately differentiated</td><td valign="top" align="left" rowspan="1" colspan="1">126</td><td valign="top" align="left" rowspan="1" colspan="1">190</td><td valign="top" align="left" rowspan="1" colspan="1">2.111 (0.909&#x02013;4.901)</td><td valign="top" align="left" rowspan="1" colspan="1">0.082</td><td valign="top" align="left" rowspan="1" colspan="1">316</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1.350 (0.688&#x02013;2.648)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Poorly differentiated</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">14 (1.536&#x02013;127.621)</td><td valign="top" align="left" rowspan="1" colspan="1">0.019</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.203 (0.370&#x02013;3.908)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serum AFP<xref ref-type="table-fn" rid="tfn12-cmar-10-953">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.499</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02264;400 (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">87</td><td valign="top" align="left" rowspan="1" colspan="1">110</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">197</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;400 (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">105</td><td valign="top" align="left" rowspan="1" colspan="1">1.432 (0.935&#x02013;2.193)</td><td valign="top" align="left" rowspan="1" colspan="1">0.099</td><td valign="top" align="left" rowspan="1" colspan="1">163</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">1.111 (0.817&#x02013;1.512)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antiviral therapy</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">95</td><td valign="top" align="left" rowspan="1" colspan="1">157</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">252</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">59</td><td valign="top" align="left" rowspan="1" colspan="1">76</td><td valign="top" align="left" rowspan="1" colspan="1">0.779 (0.51&#x02013;1.192)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25</td><td valign="top" align="left" rowspan="1" colspan="1">135</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">0.574 (0.398&#x02013;0.828)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Tumor behavior</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor size</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02264;5 cm</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">85</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">157</td><td valign="top" align="left" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;5 cm</td><td valign="top" align="left" rowspan="1" colspan="1">82</td><td valign="top" align="left" rowspan="1" colspan="1">148</td><td valign="top" align="left" rowspan="1" colspan="1">1.529 (1.011&#x02013;2.313)</td><td valign="top" align="left" rowspan="1" colspan="1">0.044</td><td valign="top" align="left" rowspan="1" colspan="1">230</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">1.757 (1.278&#x02013;2.415)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor number</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Single</td><td valign="top" align="left" rowspan="1" colspan="1">111</td><td valign="top" align="left" rowspan="1" colspan="1">169</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">280</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Multiple</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">0.978 (0.62&#x02013;1.54)</td><td valign="top" align="left" rowspan="1" colspan="1">0.922</td><td valign="top" align="left" rowspan="1" colspan="1">107</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">1.788 (1.310&#x02013;2.439)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Status of tumor capsule</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.131</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Complete</td><td valign="top" align="left" rowspan="1" colspan="1">126</td><td valign="top" align="left" rowspan="1" colspan="1">201</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">327</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Incomplete</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">0.716 (0.412&#x02013;1.247)</td><td valign="top" align="left" rowspan="1" colspan="1">0.238</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">35</td><td valign="top" align="left" rowspan="1" colspan="1">1.335 (0.914&#x02013;1.949)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regional invasion</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.421</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Absence</td><td valign="top" align="left" rowspan="1" colspan="1">131</td><td valign="top" align="left" rowspan="1" colspan="1">199</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">330</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Presence</td><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">34</td><td valign="top" align="left" rowspan="1" colspan="1">0.973 (0.549&#x02013;1.726)</td><td valign="top" align="left" rowspan="1" colspan="1">0.926</td><td valign="top" align="left" rowspan="1" colspan="1">57</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">1.185 (0.781&#x02013;1.800)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BCLC stage</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;A</td><td valign="top" align="left" rowspan="1" colspan="1">87</td><td valign="top" align="left" rowspan="1" colspan="1">129</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">216</td><td valign="top" align="left" rowspan="1" colspan="1">95</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;B</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">0.915 (0.523&#x02013;1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.756</td><td valign="top" align="left" rowspan="1" colspan="1">66</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">2.080 (1.395&#x02013;3.102)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;C</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">66</td><td valign="top" align="left" rowspan="1" colspan="1">1.141 (0.706&#x02013;1.845)</td><td valign="top" align="left" rowspan="1" colspan="1">0.59</td><td valign="top" align="left" rowspan="1" colspan="1">105</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">2.672 (1.919&#x02013;3.720)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PVTT</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">130</td><td valign="top" align="left" rowspan="1" colspan="1">189</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">319</td><td valign="top" align="left" rowspan="1" colspan="1">73</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">1.261 (0.731&#x02013;2.175)</td><td valign="top" align="left" rowspan="1" colspan="1">0.404</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">2.233 (1.615&#x02013;3.088)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn8-cmar-10-953"><label>a</label><p>Child&#x02013;Pugh class was unavailable in 24 patients. Information of</p></fn><fn id="tfn9-cmar-10-953"><label>b</label><p>radical resection was unavailable in 11 patients,</p></fn><fn id="tfn10-cmar-10-953"><label>c</label><p>portal hypertension was unavailable in 32 patients,</p></fn><fn id="tfn11-cmar-10-953"><label>d</label><p>pathological diagnosis was unavailable in 36 patients,</p></fn><fn id="tfn12-cmar-10-953"><label>e</label><p>serum AFP level was unavailable in 27 patients.</p></fn><fn id="tfn13-cmar-10-953"><p><bold>Abbreviations:</bold> GWAS, genome-wide association study; BMI, body mass index; AFP, &#x003b1;-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NA, not applicable; TP53, tumor protein p53; MST, median survival time.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-cmar-10-953" position="float"><label>Table 5</label><caption><p>Survival analysis of different haplotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Haplotypes</th><th valign="top" align="left" rowspan="1" colspan="1">Patients (2n=774)</th><th valign="top" align="left" rowspan="1" colspan="1">MST (months)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude <italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted <italic>P</italic>-value<xref ref-type="table-fn" rid="tfn14-cmar-10-953">a</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC</td><td valign="top" align="left" rowspan="1" colspan="1">616</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GT</td><td valign="top" align="left" rowspan="1" colspan="1">158</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">0.913 (0.702&#x02013;1.187)</td><td valign="top" align="left" rowspan="1" colspan="1">0.497</td><td valign="top" align="left" rowspan="1" colspan="1">0.934 (0.714&#x02013;1.221)</td><td valign="top" align="left" rowspan="1" colspan="1">0.618</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 2</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AGAGA</td><td valign="top" align="left" rowspan="1" colspan="1">356</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AGTCC</td><td valign="top" align="left" rowspan="1" colspan="1">283</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">0.930 (0.735&#x02013;1.176)</td><td valign="top" align="left" rowspan="1" colspan="1">0.544</td><td valign="top" align="left" rowspan="1" colspan="1">0.915 (0.717&#x02013;1.170)</td><td valign="top" align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GATCC+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">135</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.198 (0.909&#x02013;1.580)</td><td valign="top" align="left" rowspan="1" colspan="1">0.199</td><td valign="top" align="left" rowspan="1" colspan="1">1.153 (0.867&#x02013;1.533)</td><td valign="top" align="left" rowspan="1" colspan="1">0.327</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 3</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AG</td><td valign="top" align="left" rowspan="1" colspan="1">447</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GA+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">327</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.132 (0.918&#x02013;1.396)</td><td valign="top" align="left" rowspan="1" colspan="1">0.247</td><td valign="top" align="left" rowspan="1" colspan="1">1.121 (0.903&#x02013;1.392)</td><td valign="top" align="left" rowspan="1" colspan="1">0.299</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 4</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CC</td><td valign="top" align="left" rowspan="1" colspan="1">725</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TT+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">49</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">1.566 (1.070&#x02013;2.292)</td><td valign="top" align="left" rowspan="1" colspan="1">0.021</td><td valign="top" align="left" rowspan="1" colspan="1">1.450 (0.970&#x02013;2.167)</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn14-cmar-10-953"><label>a</label><p>Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.</p></fn><fn id="tfn15-cmar-10-953"><p><bold>Abbreviations:</bold> BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-cmar-10-953" position="float"><label>Table 6</label><caption><p>Joint effects survival analysis of different haplotypes and TP53 expression status</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">Haplotypes</th><th valign="top" align="left" rowspan="1" colspan="1">TP53 status</th><th valign="top" align="left" rowspan="1" colspan="1">Patients (2n=774)</th><th valign="top" align="left" rowspan="1" colspan="1">MST (months)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Crude <italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Adjusted <italic>P</italic>-value<xref ref-type="table-fn" rid="tfn16-cmar-10-953">a</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group 1</td><td valign="top" align="left" rowspan="1" colspan="1">TC</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">229</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group 2</td><td valign="top" align="left" rowspan="1" colspan="1">TC</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">387</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">1.107 (0.868&#x02013;1.413)</td><td valign="top" align="left" rowspan="1" colspan="1">0.413</td><td valign="top" align="left" rowspan="1" colspan="1">1.104 (0.855&#x02013;1.425)</td><td valign="top" align="left" rowspan="1" colspan="1">0.449</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group 3</td><td valign="top" align="left" rowspan="1" colspan="1">GT</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">0.845 (0.567&#x02013;1.260)</td><td valign="top" align="left" rowspan="1" colspan="1">0.409</td><td valign="top" align="left" rowspan="1" colspan="1">0.857 (0.570&#x02013;1.289)</td><td valign="top" align="left" rowspan="1" colspan="1">0.459</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group 4</td><td valign="top" align="left" rowspan="1" colspan="1">GT</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.126 (0.771&#x02013;1.644)</td><td valign="top" align="left" rowspan="1" colspan="1">0.539</td><td valign="top" align="left" rowspan="1" colspan="1">1.158 (0.787&#x02013;1.706)</td><td valign="top" align="left" rowspan="1" colspan="1">0.456</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 2</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group A</td><td valign="top" align="left" rowspan="1" colspan="1">AGAGA</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">118</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group B</td><td valign="top" align="left" rowspan="1" colspan="1">AGAGA</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">238</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">1.302 (0.928&#x02013;1.827)</td><td valign="top" align="left" rowspan="1" colspan="1">0.126</td><td valign="top" align="left" rowspan="1" colspan="1">1.206 (0.854&#x02013;1.704)</td><td valign="top" align="left" rowspan="1" colspan="1">0.288</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group C</td><td valign="top" align="left" rowspan="1" colspan="1">AGTCC+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">190</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1.171 (0.818&#x02013;1.675)</td><td valign="top" align="left" rowspan="1" colspan="1">0.389</td><td valign="top" align="left" rowspan="1" colspan="1">1.057 (0.733&#x02013;1.524)</td><td valign="top" align="left" rowspan="1" colspan="1">0.765</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group D</td><td valign="top" align="left" rowspan="1" colspan="1">AGTCC+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">228</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">1.256 (0.892&#x02013;1.769)</td><td valign="top" align="left" rowspan="1" colspan="1">0.191</td><td valign="top" align="left" rowspan="1" colspan="1">1.199 (0.841&#x02013;1.709)</td><td valign="top" align="left" rowspan="1" colspan="1">0.316</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 3</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group i</td><td valign="top" align="left" rowspan="1" colspan="1">AG</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">156</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group ii</td><td valign="top" align="left" rowspan="1" colspan="1">AG</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">291</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">1.243 (0.920&#x02013;1.678)</td><td valign="top" align="left" rowspan="1" colspan="1">0.156</td><td valign="top" align="left" rowspan="1" colspan="1">1.329 (0.976&#x02013;1.811)</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group iii</td><td valign="top" align="left" rowspan="1" colspan="1">GA+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">152</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">1.235 (0.875&#x02013;1.743)</td><td valign="top" align="left" rowspan="1" colspan="1">0.23</td><td valign="top" align="left" rowspan="1" colspan="1">1.341 (0.943&#x02013;1.905)</td><td valign="top" align="left" rowspan="1" colspan="1">0.102</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group iv</td><td valign="top" align="left" rowspan="1" colspan="1">GA+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">175</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">1.380 (0.993&#x02013;1.918)</td><td valign="top" align="left" rowspan="1" colspan="1">0.055</td><td valign="top" align="left" rowspan="1" colspan="1">1.361 (0.971&#x02013;1.908)</td><td valign="top" align="left" rowspan="1" colspan="1">0.074</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Block 4</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group I</td><td valign="top" align="left" rowspan="1" colspan="1">CC</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">279</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group II</td><td valign="top" align="left" rowspan="1" colspan="1">CC</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">446</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">1.196 (0.953&#x02013;1.501)</td><td valign="top" align="left" rowspan="1" colspan="1">0.123</td><td valign="top" align="left" rowspan="1" colspan="1">1.261 (0.995&#x02013;1.599)</td><td valign="top" align="left" rowspan="1" colspan="1">0.055</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group III</td><td valign="top" align="left" rowspan="1" colspan="1">TT+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">1.677 (0.992&#x02013;2.834)</td><td valign="top" align="left" rowspan="1" colspan="1">0.054</td><td valign="top" align="left" rowspan="1" colspan="1">1.713 (1.006&#x02013;2.918)</td><td valign="top" align="left" rowspan="1" colspan="1">0.047</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group IV</td><td valign="top" align="left" rowspan="1" colspan="1">TT+other haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">1.855 (1.045&#x02013;3.294)</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">1.651 (0.872&#x02013;3.126)</td><td valign="top" align="left" rowspan="1" colspan="1">0.123</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn16-cmar-10-953"><label>a</label><p>Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.</p></fn><fn id="tfn17-cmar-10-953"><p><bold>Abbreviations:</bold> TP53, tumor protein p53; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time.</p></fn></table-wrap-foot></table-wrap></floats-group></article>